Kinetics and prognostic value of soluble VCAM ‐1 in ST‐segment elevation myocardial infarction patients

ConclusionsIn STEMI patients, high sVCAM ‐1 levels are associated with a poor clinical outcome. sVCAM‐1 is an early postmyocardial infarction biomarker and might be an interesting target for the development of future therapeutic strategies.

Source: Immunity, Inflammation and Disease - February 9, 2021 Category: Allergy & Immunology Authors: Ahmad Hayek, Alexandre Paccalet, Laura Mechtouff, Claire C. Da Silva, Fabrice Ivanes, Hadrien Falque, Simon Leboube, Yvonne Varillon, Camille Amaz, Charles Bourguignon, Cyril Prieur, Danka Tomasevic, Nathalie Genot, Fran çois Derimay, Eric Tags: ORIGINAL RESEARCH Source Type: research